Dra. Ana Maria Kausel walks through common errors people make on GLP-1 drugs, covering Ozempic, Mounjaro, Wegovy and Zepbound.
Recap by typeshit. Full story at Dra. Ana Maria Kausel.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
A short social post on whether appetite from cannabis changes when someone is on a GLP-1 medication. There is no detail or source behind it.
The drug is still in clinical trials, yet wellness clinics are promoting and dispensing copies, and state regulators haven't stepped in, the paper reports.
Loading…